Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 8Other hematologic neoplasm 5Plasma cell 4Thoracic 3Gastrointestinal 3Tumor-Agnostic 1Myeloid 1Gynecologic 1

Conditions

Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 134pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Letrozole 28Drug Therapy 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23durvalumab 22Albumin-Bound Paclitaxel 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20Specimen Handling 20Filgrastim 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Maintenance × Gynecologic × Clear all
NCT03983226 2022-03-18

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
167 enrolled
Gynecologic

Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡